New York, NY (June 4, 2024) – The European Academy of Allergy and Clinical Immunology (EAACI) has awarded Emma Guttman-Yassky, MD, Ph.D., the prestigious Paul Ehrlich Award for Experimental Research at its 2024 Annual Congress in Valencia, Spain. This award celebrates groundbreaking contributions to the understanding of allergic diseases and immunological mechanisms.
Dr. Guttman-Yassky holds the Waldman Chair of Dermatology at the Icahn School of Medicine at Mount Sinai and serves as a Professor of Dermatology and Immunology. She is also the Director of the Eczema Center, the Contact Dermatitis Clinic, and the Laboratory for Inflammatory Skin Diseases at Mount Sinai.
The Paul Ehrlich Award honors scientists whose experimental research has transformed the understanding and treatment of allergic diseases. Named after Paul Ehrlich, a Nobel Prize-winning physician renowned for his work in hematology, immunology, and antimicrobial chemotherapy, the award recognizes fearless exploration and innovative experimentation in the field of allergology and clinical immunology.
Dr. Guttman-Yassky’s personal and family experiences with eczema and other allergic conditions have fueled her dedication to this field. “I have made it my mission to alleviate the suffering of patients with eczema and sensitive skin diseases, as well as other diseases associated with the atopic spectrum,” she said. “It’s a dream come true to see patients all over the world feel and look better, thanks to the array of new treatment options emerging.”
Renowned as a leading expert in inflammatory skin diseases, Dr. Guttman-Yassky has made significant strides in understanding the immunologic basis of atopic dermatitis (AD) and other skin conditions. Her research has led to breakthroughs in the treatment of AD/eczema, alopecia areata, chronic hand eczema, and other rare skin diseases. Her approach, combining bench-to-bedside research, has accelerated the development of new, effective treatments.
At the 2024 EAACI Congress, which focused on “Revolutionizing Patient Care Through the Power of Data Science,” Dr. Guttman-Yassky presented on JAK inhibitors and skin biomarkers during the “New Horizons in Skin Disorders” session. Her work continues to influence the field, enhancing personalized care and integrating data science in allergy and clinical immunology.
In addition to the Paul Ehrlich Award, Dr. Guttman-Yassky received the first Therapeutic Innovation Award from the American Skin Association (ASA) in April. This recognition honors her contributions to understanding the molecular and cellular mechanisms of inflammatory skin diseases.
The EAACI is the world’s largest organization dedicated to allergy research and education, with over 15,000 members from 124 countries. The EAACI Awards celebrate eminent scientists who have significantly advanced the field of allergy and clinical immunology.
Related Topics:
